Adial Pharmaceuticals (NASDAQ:ADIL) reported a significant reduction in annual net losses for 2025, as the clinical-stage biotech firm secures FDA alignment and strategic partnerships to transition its lead alcohol-use disorder candidate into Phase 3 trials.
The company announced Friday that its full-year 2025 net loss narrowed to $8 million, a substantial improvement from the $13.2 million loss reported in 2024.
The Virginia-based company, which focuses on genetically targeted therapies for addiction, attributed the improved fiscal standing to a 19% reduction in research and development expenses and a refined operational strategy.
The 2025 fiscal year was marked by several critical regulatory and clinical milestones for the company’s lead investigational drug, AD04.
Key achievements included positive pharmacokinetics (PK) results from the AD04-103 study and productive End-of-Phase 2 engagement with the U.S. Food and Drug Administration (FDA).
The agency provided supportive feedback on an in vitro bridging strategy, potentially streamlining the path to registrational trials.
On the operational front, Adial fortified its infrastructure by securing U.S.-based manufacturing partnerships with Cambrex and Thermo Fisher Scientific.
The company also expanded its intellectual property moat, filing a Patent Cooperation Treaty (PCT) application that could extend international protection for its core assets through at least 2045.
Adial ended the year with $5.9 million in cash and equivalents, up from $3.8 million at the end of 2024.
Management expects this liquidity to provide a cash runway into the second half of 2026, covering the initiation of Phase 3 planning and ongoing partnership discussions, including a recent framework agreement with Molteni Farmaceutici for potential commercialization in Europe.